Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Vir Biotechnology Inc shares valued at $8,533,886 were purchased by SVF Endurance (Cayman) Limited on Jan 14 ’26. At $6.82 per share, SVF Endurance (Cayman) Limited acquired 1,251,303 shares.
Also, SATO VICKI L sold 22,000 shares, netting a total of over 130,383 in proceeds. Following the sale of shares at $5.93 each, the insider now holds 1,166,391 shares.
Before that, VICKI LEE SATO had added 66,000 shares to its account. In a trade valued at $397,980, the Director bought Vir Biotechnology Inc shares for $6.03 each.
As published in their initiating research note from Evercore ISI on September 03, 2025, Vir Biotechnology Inc [VIR] has been an Outperform and the price target has been revised to $12. Analysts at BofA Securities upgraded the stock from ‘”a Neutral”‘ to ‘”a Buy”‘ outlook in a report released in late August. As of January 29, 2024, JP Morgan has decreased its “an Overweight” rating to a “Neutral” for VIR. Earlier on September 08, 2023, BofA Securities downgraded its rating. Their new recommendation was “a Neutral” for VIR stock which previously was a “a Buy”.
Analyzing VIR Stock Performance
On last trading session, Vir Biotechnology Inc [NASDAQ: VIR] rose 15.67% to $6.94. The stock’s lowest price that day was $5.97, but it reached a high of $6.9799 in the same session. During the last five days, there has been a surge of approximately 9.98%. Over the course of the year, Vir Biotechnology Inc shares have dropped approximately -31.36%.
Is Vir Biotechnology Inc subject to short interest?
Stocks of Vir Biotechnology Inc saw a sharp rise in short interest on 2025-12-31 jumping by 0.64 million shares to 11.75 million. Data from Yahoo Finance shows that the short interest on 2025-11-28 was 11.11 million shares. A jump of 5.42% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 6.06 of the overall float, the days-to-cover ratio (short ratio) jumped to 6.06.
Which companies own the most shares of Vir Biotechnology Inc (VIR)?
In terms of Vir Biotechnology Inc share price expectations, FactSet research, analysts set an average price target of 15 in the next 12 months, up nearly 150.0% from the previous closing price of $6.0. Analysts anticipate Vir Biotechnology Inc stock to reach 15 by 2026, with the lowest price target being 15. In spite of this, 10 analysts ranked Vir Biotechnology Inc stock as Buy at the end of 2026. On March 06, 2023, JP Morgan assigned a price target of “an Overweight” to the stock and upgraded coverage with a $34.
